Show simple item record

dc.contributor.authorFreeman, K
dc.contributor.authorConnock, M
dc.contributor.authorCummins, E
dc.contributor.authorGurung, T
dc.contributor.authorTaylor-Phillips, S
dc.contributor.authorCourt, R
dc.contributor.authorSaunders, Mark P
dc.contributor.authorClarke, A
dc.contributor.authorSutcliffe, P
dc.date.accessioned2016-01-06T10:29:03Zen
dc.date.available2016-01-06T10:29:03Zen
dc.date.issued2015-11en
dc.identifier.citationFluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. 2015, 19 (91):1-322 Health Technol Assessen
dc.identifier.issn2046-4924en
dc.identifier.pmid26542268en
dc.identifier.doi10.3310/hta19910en
dc.identifier.urihttp://hdl.handle.net/10541/592937en
dc.description.abstract5-Fluorouracil (5-FU) is a chemotherapy used in colorectal, head and neck (H&N) and other cancers. Dose adjustment is based on body surface area (BSA) but wide variations occur. Pharmacokinetic (PK) dosing is suggested to bring plasma levels into the therapeutic range to promote fewer side effects and better patient outcomes. We investigated the clinical effectiveness and cost-effectiveness of the My5-FU assay for PK dose adjustment to 5-FU therapy.
dc.language.isoenen
dc.rightsArchived with thanks to Health technology assessment (Winchester, England)en
dc.titleFluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion.en
dc.typeArticleen
dc.contributor.departmentWarwick Medical School, University of Warwick, Coventryen
dc.identifier.journalHealth Technology Assessmenten
html.description.abstract5-Fluorouracil (5-FU) is a chemotherapy used in colorectal, head and neck (H&N) and other cancers. Dose adjustment is based on body surface area (BSA) but wide variations occur. Pharmacokinetic (PK) dosing is suggested to bring plasma levels into the therapeutic range to promote fewer side effects and better patient outcomes. We investigated the clinical effectiveness and cost-effectiveness of the My5-FU assay for PK dose adjustment to 5-FU therapy.


This item appears in the following Collection(s)

Show simple item record